

# Contents

<i>List of Contributors</i>	<b>xv</b>
<i>Foreword</i>	<b>xvii</b>
<b>1 An Introduction to Biopharmaceutics</b>	<b>1</b>
<i>Hannah Batchelor</i>	
1.1 Introduction	1
1.2 History of Biopharmaceutics	1
1.3 Key Concepts and Definitions Used Within Biopharmaceutics	3
1.4 The Role of Biopharmaceutics in Drug Development	6
1.5 Conclusions	8
References	8
<b>2 Basic Pharmacokinetics</b>	<b>9</b>
<i>Hamid A. Merchant</i>	
2.1 Introduction	9
2.2 What is 'Pharmacokinetics'?	9
2.3 Pharmacokinetic Profile	10
2.4 Bioavailability	12
2.5 Drug Distribution	14
2.6 Volume of Distribution	15
2.7 Elimination	17
2.7.1 Metabolism	17
2.7.2 Excretion	17
2.8 Elimination Half-Life ( $t_{1/2}$ )	19
2.9 Elimination Rate Constant	19
2.9.1 Clearance	21
2.10 Area Under the Curve (AUC)	22

2.11	Bioequivalence	22
2.12	Steady State	23
2.13	Compartmental Concepts in Pharmacokinetics	25
2.14	Concept of Linearity in Pharmacokinetics	27
2.15	Conclusions	28
	Further Reading	29
<b>3</b>	<b>Introduction to Biopharmaceutics Measures</b>	<b>31</b>
	<i>Hannah Batchelor and Pavel Gershkovich</i>	
3.1	Introduction	31
3.2	Solubility	31
3.3	Dissolution	33
3.4	Permeability	34
3.5	Absorptive Flux	35
3.6	Lipinsky's Rule of 5	36
3.6.1	Molecular Weight	36
3.6.2	Lipophilicity	36
3.6.3	Hydrogen Bond Donors/Acceptors	37
	References	37
<b>4</b>	<b>Solubility</b>	<b>39</b>
	<i>Hannah Batchelor</i>	
4.1	Definition of Solubility	39
4.2	The Importance of Solubility in Biopharmaceutics	39
4.3	What Level of Solubility Is Required?	40
4.4	Solubility-Limited Absorption	41
4.5	Methods to Assess Solubility	41
4.6	Brief Overview of Forces Involved in Solubility	42
4.6.1	van der Waals Interactions	42
4.6.2	Hydrogen Bonding	42
4.6.3	Ionic Interactions	43
4.7	Solid-State Properties and Solubility	43
4.8	pH and Drug Solubility	43
4.9	Solvents	44
4.9.1	Biorelevant Solubility	45
4.9.2	Buffer System – Phosphate vs Bicarbonate	46
4.9.3	Solubilisation by Surfactants	46
4.9.4	Solubilisation During Digestion	47
4.9.5	Excipients and Solubility	47
4.10	Risk of Precipitation	48
4.11	Solubility and Link to Lipophilicity	49
4.12	Conclusions	49
	References	49
<b>5</b>	<b>Permeability</b>	<b>51</b>
	<i>Chris Roe and Vanessa Zann</i>	
5.1	Introduction	51

5.2	Enzymes, Gut Wall Metabolism, Tissue Permeability and Transporters	52
5.2.1	Enzymes	52
5.2.2	Drug Transporters	54
5.2.3	Efflux Transporters	55
5.2.4	Transporters of Greatest Relevance to Oral Biopharmaceutics	56
5.2.5	Regulatory Overview of Transporter Effects on Biopharmaceutics	58
5.2.6	Regional Expression and Polymorphism of Intestinal Transporters and Impact of Drug Variability	59
5.3	Applications and Limitations of Characterisation and Predictive Tools for Permeability Assessment	59
5.3.1	<i>In Silico</i> Tools: Predictive Models for Permeability	60
5.3.2	<i>In Vitro</i> Tools	60
5.3.2.1	PAMPA	60
5.3.2.2	Cell Lines	61
5.3.3	<i>Ex Vivo</i> Tools	63
5.3.3.1	Ussing Chambers	63
5.3.3.2	Everted Intestinal Sac/Ring	65
5.3.4	<i>In Situ</i> Tools	66
5.3.4.1	Closed-Loop Intestinal Perfusion	66
5.3.4.2	Single-Pass Intestinal Perfusion	67
5.3.4.3	Intestinal Perfusion with Venous Sampling	67
5.3.4.4	Vascularly Perfused Intestinal Models	68
5.4	<i>In Vivo</i> Tools	68
5.5	Conclusion	69
	References	69
<b>6</b>	<b>Dissolution</b>	<b>73</b>
	<i>Hannah Batchelor and James Butler</i>	
6.1	Introduction	73
6.2	Purpose of Dissolution Testing	73
6.2.1	Dissolution Versus Solubility	74
6.3	History of Dissolution Testing	75
6.4	Compendial (Pharmacopeial) Dissolution Apparatus	76
6.4.1	USP1 and 2 Apparatus	76
6.4.2	USP3 Apparatus	78
6.4.3	USP4 Apparatus	79
6.4.4	USP5 Apparatus	80
6.4.5	USP6 Apparatus	80
6.4.6	USP7 Apparatus	80
6.4.7	Intrinsic Dissolution Rate (IDR) Apparatus	80
6.4.8	Micro-dissolution Apparatus	81
6.5	Dissolution Media Selection	81
6.5.1	Biphasic Dissolution Media	82
6.6	Dissolution Agitation Rates	82
6.7	Reporting Dissolution Data	83
6.8	<i>In Vitro In Vivo</i> Relationships and Correlations (IVIVR/IVIVC)	84

6.8.1	Convolution and Deconvolution of Dissolution Data	85
6.9	Evolution of Biorelevant Dissolution Testing	86
6.9.1	Biorelevant Dissolution Media	86
6.9.2	Dissolution Testing to Mimic GI Transit	90
6.9.3	Dissolution Testing to Mimic Motility/Hydrodynamic Conditions	92
6.9.4	Dissolution Testing to Incorporate Permeability	93
6.10	Conclusions	93
	References	94
<b>7</b>	<b>Biopharmaceutics to Inform Candidate Drug Selection and Optimisation</b>	<b>99</b>
	<i>Linette Ruston</i>	
7.1	Introduction	99
7.2	Oral Product Design Considerations During Early Development	100
7.3	Biopharmaceutics in Drug Discovery	101
7.3.1	Pre-Clinical Studies	102
7.4	Biopharmaceutics Assessment	103
7.4.1	Solubility	103
7.4.2	Permeability	104
7.4.3	Dissolution	104
7.4.4	Biopharmaceutics Classification System	104
7.4.5	Lipophilicity	104
7.4.6	$pK_a$	105
7.4.7	Molecular Size	105
7.4.8	Crystallinity	105
7.4.9	<i>In Vivo</i> Pre-Clinical Studies	106
7.4.10	<i>In Silico</i> Modelling	106
7.4.11	Human Absorption/Dose Prediction	106
7.5	Output of Biopharmaceutics Assessment	107
7.5.1	New Modalities/Complex Delivery Systems Within Early Development	107
7.6	Influence/Optimise/Design Properties to Inform Formulation Development	108
7.6.1	Fraction Absorbed Classification System	110
7.7	Conclusion	110
	References	110
<b>8</b>	<b>Biopharmaceutics Tools for Rational Formulation Design</b>	<b>113</b>
	<i>Panagiota Zarnpi, Mark McAllister, James Butler and Nikoletta Fotaki</i>	
8.1	Introduction	113
8.2	Formulation Development to Optimise Drug Bioavailability	115
8.3	Traditional Formulation Strategies	115
8.3.1	Decision Making for Conventional or Enabling Formulations	115
8.4	Decision Trees to Guide Formulation Development	115
8.4.1	Decision Trees Based on Biopharmaceutics Classification System (BCS)	115
8.4.2	Decision Trees Based on Developability Classification System (DCS)	117

8.4.3	Expanded Decision Trees	120
8.5	Computational Tools to Guide Formulation Strategies	120
8.5.1	Statistical Tools	120
8.5.2	Physiologically Based Pharmacokinetic/Biopharmaceutics Models	121
8.6	Decision-Making for Optimising Enabling Formulations	122
8.7	Decision Trees for Enabled Formulations	123
8.7.1	Statistical Tools	124
8.7.2	Physiologically Based Pharmacokinetic/Biopharmaceutics Models	124
8.8	System-Based Formulation Strategies	125
8.8.1	Quality by Design	125
8.8.2	Tools to Identify Quality Target Product Profile	125
8.9	Biopharmaceutics Risk Assessment Roadmap (BioRAM)	126
8.9.1	Tools to Identify Quality Target Product Profile	126
8.10	Conclusions	129
	References	131
<b>9</b>	<b>Biopharmaceutic Classification System</b>	<b>135</b>
	<i>Hannah Batchelor and Talia Flanagan</i>	
9.1	Description and History of the BCS	135
9.2	BCS-Based Criteria for Solubility, Dissolution and Permeability	135
9.3	BCS-Based Biowaivers	137
9.4	Regulatory Development of BCS-Based Biowaivers	138
9.5	International Harmonisation of BCS-Based Biowaiver Criteria – ICH M9	138
9.5.1	Application of BCS-Based Biowaivers	139
9.5.1.1	Drug Product Type	140
9.5.1.2	Composition	140
9.5.1.3	Dissolution Similarity	141
9.6	BCS as a Development Tool	141
9.6.1	Candidate Selection	142
9.6.2	Solid Form Selection	142
9.6.3	Product Development	142
9.7	Beyond the BCS	143
9.7.1	Biopharmaceutic Drug Disposition Classification System (BDDCS)	143
9.7.2	Developability Classification System	144
9.7.3	Fraction Absorbed Classification System	144
9.7.4	BCS Applied to Special Populations	144
9.8	Conclusions	145
	References	145
<b>10</b>	<b>Regulatory Biopharmaceutics</b>	<b>147</b>
	<i>Shanoo Budhdeo, Paul A. Dickinson and Talia Flanagan</i>	
10.1	Introduction	147
10.2	Clinical Bioequivalence Studies	148

10.3	Design of Clinical Bioequivalence (BE) Studies	150
10.4	Implication of Bioequivalence Metrics	151
10.5	Bioequivalence Regulatory Guidelines	152
10.6	Biowaivers	153
10.7	Biopharmaceutics in Quality by Design	153
10.8	Control of Drug Product and Clinically Relevant Specifications	155
10.9	Establishing Clinically Relevant Dissolution Methods and Specifications	156
10.10	Application of <i>In Silico</i> Physiologically Based Biopharmaceutics Modelling (PBBM) to Develop Clinically Relevant Specifications	159
10.11	Additional Considerations for Establishing Dissolution Methods and Specifications	159
10.12	Common Technical Document (CTD)	160
10.13	Other Routes of Administration and Locally Acting Drug Products	161
10.14	Conclusion	162
	References	162
<b>11</b>	<b>Impact of Anatomy and Physiology</b>	<b>165</b>
	<i>Francesca K. H. Gavins, Christine M. Madla, Sarah J. Trenfield, Laura E. McCoubrey, Abdul W. Basit and Mark McAllister</i>	
11.1	Introduction	165
11.2	Influence of GI Conditions on Pharmacokinetic Studies	166
11.3	The Stomach	167
	11.3.1 Gastric Anatomy	167
	11.3.2 Gastric Motility and Mixing	168
	11.3.3 Gastric Emptying	169
	11.3.3.1 Gastric Fed State	170
	11.3.4 Gastric Fluid Volume	170
	11.3.5 Gastric Temperature	171
	11.3.6 Gastric Fluid Composition	171
	11.3.6.1 Gastric pH	171
	11.3.6.2 Gastric Bile Salt Composition and Concentration	172
11.4	Small Intestine	172
	11.4.1 Small Intestinal Anatomy	172
	11.4.2 Small Intestinal Motility and Mixing	174
	11.4.3 Small Intestinal Transit Time	174
	11.4.4 Small Intestinal Volume	174
	11.4.5 Small Intestinal Fluid Composition	175
	11.4.5.1 Small Intestinal pH	176
	11.4.5.2 Small Intestinal Buffer Capacity	176
	11.4.5.3 Small Intestinal Surface Tension	176
	11.4.5.4 Small Intestinal Osmolality	176
	11.4.5.5 Bile Salt Composition and Concentration	177
11.5	The Colon/Large Intestine	177
	11.5.1 Large Intestine Anatomy	178
	11.5.2 Large Intestinal Motility and Mixing	178

11.5.3	Large Intestinal Transit Time	179
11.5.4	Large Intestinal Volume	179
11.5.5	Large Intestinal Fluid Composition	179
11.5.5.1	Large Intestinal pH	179
11.5.5.2	Large Intestinal Buffer Capacity	180
11.5.5.3	Large Intestinal Surface Tension	180
11.5.5.4	Large Intestinal Osmolality	180
11.5.5.5	Bile Salt Composition and Concentration	180
11.5.6	Impact of Microbiome on Oral Drug Delivery	181
11.6	Conclusions	182
	References	182
<b>12</b>	<b>Integrating Biopharmaceutics to Predict Oral Absorption Using PBPK Modelling</b>	<b>189</b>
	<i>Konstantinos Stamatopoulos</i>	
12.1	Introduction	189
12.2	Mechanistic Models	190
12.3	Solubility Inputs	192
12.4	Dissolution Inputs	196
12.4.1	Fluid Dynamics and Dissolution	198
12.5	Permeability Inputs	198
12.6	Incorporation of Modelling and Simulation into Drug Development	200
12.6.1	Understanding the Effect of Formulation Modifications on Drug Pharmacokinetics	200
12.6.2	Model Verification/Validation	201
12.6.3	Using Modelling to Understand Bioequivalence	201
12.7	Conclusions	202
	References	202
<b>13</b>	<b>Special Populations</b>	<b>205</b>
	<i>Christine M. Madla, Francesca K. H. Gavins, Sarah J. Trenfield and Abdul W. Basit</i>	
13.1	Introduction	205
13.2	Sex Differences in the Gastrointestinal Tract and Its Effect on Oral Drug Performance	206
13.3	Ethnic Differences in the Gastrointestinal Tract	208
13.4	Impact of Diet on Gastrointestinal Physiology	209
13.5	Pregnancy and Its Effect on Gastrointestinal Physiology	211
13.6	The Implication of Disease States on Gastrointestinal Physiology and Its Effect on Oral Drug Performance	212
13.7	Diseases that Affect the Gastrointestinal Tract	212
13.7.1	Irritable Bowel Syndrome	212
13.7.2	Inflammatory Bowel Disease	213
13.7.3	Celiac Disease	215
13.8	Infections in the Gastrointestinal Tract	216
13.8.1	<i>Helicobacter pylori</i> Infection	216

13.9	Systemic Diseases that Alter GI Physiology and Function	216
13.9.1	Cystic Fibrosis	217
13.9.2	Parkinson's Disease	218
13.9.3	Diabetes	219
13.9.4	HIV Infection	221
13.10	Age-related Influences on Gastrointestinal Tract Physiology and Function	222
13.10.1	Gastrointestinal Physiology and Function in Paediatrics	222
13.10.2	Gastrointestinal Physiology and Function in Geriatrics	224
13.11	Conclusion	226
	References	226
<b>14</b>	<b>Inhalation Biopharmaceutics</b>	<b>239</b>
	<i>Precious Akhuemokhan, Magda Swedrowska, and Ben Forbes</i>	
14.1	Introduction	239
14.2	Structure of the Lungs	240
14.2.1	Basic Anatomy	240
14.2.2	Epithelial Lining Fluid	241
14.2.3	Epithelium	241
14.3	Molecules, Inhalation Devices, Formulations	241
14.3.1	Inhaled Molecules	241
14.3.2	Inhalation Devices	242
14.3.2.1	Nebulisers	242
14.3.2.2	Pressurised Metered-Dose Inhalers	243
14.3.2.3	Dry Powder Inhalers	243
14.3.2.4	'Soft Mist' Inhalers	243
14.3.3	Inhaled Medicine Formulation	243
14.4	Inhaled Drug Delivery and Models for Studying Inhalation Biopharmaceutics	244
14.4.1	Dosimetry and Deposition	244
14.4.2	Mucociliary Clearance	245
14.4.3	Dissolution	246
14.4.4	Lung Permeability, Absorption and Retention	247
14.4.5	Metabolism	248
14.4.6	Non-Clinical Inhalation Studies	248
14.4.7	Mechanistic Computer Modelling	249
14.5	Bioequivalence and an Inhalation Bioclassification System	249
14.6	Conclusion	249
	References	250
<b>15</b>	<b>Biopharmaceutics of Injectable Formulations</b>	<b>253</b>
	<i>Wang Wang Lee and Claire M. Patterson</i>	
15.1	Introduction	253
15.2	Subcutaneous Physiology and Absorption Mechanisms	256
15.2.1	Physiology	256
15.2.2	Absorption Mechanisms	257

15.3	Intramuscular Physiology and Absorption Mechanisms	258
15.3.1	Physiology	258
15.3.2	Absorption Mechanisms	259
15.4	<i>In Vitro</i> Performance and IVIVC	259
15.4.1	<i>In Silico</i> Models	261
15.4.2	Preclinical Models	261
15.5	Bioequivalence of Injectable Formulations	261
15.6	Summary	262
	References	262
<b>16</b>	<b>Biopharmaceutics of Topical and Transdermal Formulations</b>	<b>265</b>
	<i>Hannah Batchelor</i>	
16.1	Introduction	265
16.2	Skin Structure	266
16.2.1	Transport of Drugs Through Skin	267
16.2.2	Skin Metabolism	267
16.3	Active Pharmaceutical Ingredient Properties	267
16.4	Topical and Transdermal Dosage Forms	267
16.5	Measurement of <i>In Vitro</i> Drug Release	268
16.5.1	Diffusion Cells	268
16.5.2	Compendial Dissolution Apparatus	269
16.6	Measurement of Skin Permeation	269
16.6.1	Tape-Stripping ‘Dermatopharmacokinetics’ (DPK)	270
16.6.2	Confocal Laser Scanning Microscopy (CLSM)	270
16.6.3	Diffusion Cells Using Biorelevant Membranes to Model Permeation	270
16.6.3.1	Alternative Skin Substrates Used for Permeability Studies	270
16.6.4	Dermal Microdialysis	271
16.6.5	Skin Biopsy	271
16.6.6	<i>In Silico</i> Models of Dermal Absorption	271
16.6.7	Pre-Clinical Models	272
16.7	Bioequivalence Testing of Topical/Transdermal Products	273
16.8	Conclusions	274
	References	274
<b>17</b>	<b>Impact of the Microbiome on Oral Biopharmaceutics</b>	<b>277</b>
	<i>Laura E. McCoubrey, Hannah Batchelor, Abdul W. Basit, Simon Gaisford and Mine Orlu</i>	
17.1	Introduction	277
17.2	Microbiome Distribution in the GI Tract	278
17.3	Key Causes of Microbiome Variability	280
17.4	Microbiome Influence on Key GI Parameters	281
17.4.1	pH	281
17.4.2	Bile Acid Concentration and Composition	281
17.4.3	Drug Transporters	283

282	17.4.4	Motility	283
282	17.4.5	Hepatic Drug Metabolism	283
282	17.4.6	Epithelial Permeability	284
282	17.5	Enzymatic Degradation of Drugs by GI Microbiota	284
282	17.6	Exploitation of the GI Microbiome for Drug Delivery	285
282	17.7	Models of the GI Microbiome	285
282	17.7.1	<i>In Vitro</i> Models	285
282	17.7.2	<i>In Silico</i> Models	289
282	17.8	Conclusion	289
		References	290

**Index**

297			<b>297</b>
297	18.1	Introduction	297
297	18.2	Skin Structure and Drug Delivery	297
297	18.2.1	Transport of Drugs Through Skin	297
297	18.2.2	Skin Metabolism	297
297	18.2.3	Pharmaceutical Injections	297
297	18.2.4	Physical and Transdermal Drug Delivery	297
297	18.2.5	Mechanism of <i>In Vivo</i> Drug Release	297
297	18.2.6	18.2.1 Diffusion Coefficient	297
297	18.2.7	18.2.2 Compartmental Diffusion	297
297	18.2.8	Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.9	18.2.1 Topical Drug Delivery (TDD)	297
297	18.2.10	18.2.2 Transdermal Drug Delivery (TDD)	297
297	18.2.11	18.2.3 Diffusion Coefficient	297
297	18.2.12	18.2.4 Compartmental Diffusion	297
297	18.2.13	18.2.5 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.14	18.2.6 Topical Drug Delivery (TDD)	297
297	18.2.15	18.2.7 Transdermal Drug Delivery (TDD)	297
297	18.2.16	18.2.8 Diffusion Coefficient	297
297	18.2.17	18.2.9 Compartmental Diffusion	297
297	18.2.18	18.2.10 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.19	18.2.11 Topical Drug Delivery (TDD)	297
297	18.2.20	18.2.12 Transdermal Drug Delivery (TDD)	297
297	18.2.21	18.2.13 Diffusion Coefficient	297
297	18.2.22	18.2.14 Compartmental Diffusion	297
297	18.2.23	18.2.15 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.24	18.2.16 Topical Drug Delivery (TDD)	297
297	18.2.25	18.2.17 Transdermal Drug Delivery (TDD)	297
297	18.2.26	18.2.18 Diffusion Coefficient	297
297	18.2.27	18.2.19 Compartmental Diffusion	297
297	18.2.28	18.2.20 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.29	18.2.21 Topical Drug Delivery (TDD)	297
297	18.2.30	18.2.22 Transdermal Drug Delivery (TDD)	297
297	18.2.31	18.2.23 Diffusion Coefficient	297
297	18.2.32	18.2.24 Compartmental Diffusion	297
297	18.2.33	18.2.25 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.34	18.2.26 Topical Drug Delivery (TDD)	297
297	18.2.35	18.2.27 Transdermal Drug Delivery (TDD)	297
297	18.2.36	18.2.28 Diffusion Coefficient	297
297	18.2.37	18.2.29 Compartmental Diffusion	297
297	18.2.38	18.2.30 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.39	18.2.31 Topical Drug Delivery (TDD)	297
297	18.2.40	18.2.32 Transdermal Drug Delivery (TDD)	297
297	18.2.41	18.2.33 Diffusion Coefficient	297
297	18.2.42	18.2.34 Compartmental Diffusion	297
297	18.2.43	18.2.35 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.44	18.2.36 Topical Drug Delivery (TDD)	297
297	18.2.45	18.2.37 Transdermal Drug Delivery (TDD)	297
297	18.2.46	18.2.38 Diffusion Coefficient	297
297	18.2.47	18.2.39 Compartmental Diffusion	297
297	18.2.48	18.2.40 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.49	18.2.41 Topical Drug Delivery (TDD)	297
297	18.2.50	18.2.42 Transdermal Drug Delivery (TDD)	297
297	18.2.51	18.2.43 Diffusion Coefficient	297
297	18.2.52	18.2.44 Compartmental Diffusion	297
297	18.2.53	18.2.45 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.54	18.2.46 Topical Drug Delivery (TDD)	297
297	18.2.55	18.2.47 Transdermal Drug Delivery (TDD)	297
297	18.2.56	18.2.48 Diffusion Coefficient	297
297	18.2.57	18.2.49 Compartmental Diffusion	297
297	18.2.58	18.2.50 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.59	18.2.51 Topical Drug Delivery (TDD)	297
297	18.2.60	18.2.52 Transdermal Drug Delivery (TDD)	297
297	18.2.61	18.2.53 Diffusion Coefficient	297
297	18.2.62	18.2.54 Compartmental Diffusion	297
297	18.2.63	18.2.55 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.64	18.2.56 Topical Drug Delivery (TDD)	297
297	18.2.65	18.2.57 Transdermal Drug Delivery (TDD)	297
297	18.2.66	18.2.58 Diffusion Coefficient	297
297	18.2.67	18.2.59 Compartmental Diffusion	297
297	18.2.68	18.2.60 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.69	18.2.61 Topical Drug Delivery (TDD)	297
297	18.2.70	18.2.62 Transdermal Drug Delivery (TDD)	297
297	18.2.71	18.2.63 Diffusion Coefficient	297
297	18.2.72	18.2.64 Compartmental Diffusion	297
297	18.2.73	18.2.65 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.74	18.2.66 Topical Drug Delivery (TDD)	297
297	18.2.75	18.2.67 Transdermal Drug Delivery (TDD)	297
297	18.2.76	18.2.68 Diffusion Coefficient	297
297	18.2.77	18.2.69 Compartmental Diffusion	297
297	18.2.78	18.2.70 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.79	18.2.71 Topical Drug Delivery (TDD)	297
297	18.2.80	18.2.72 Transdermal Drug Delivery (TDD)	297
297	18.2.81	18.2.73 Diffusion Coefficient	297
297	18.2.82	18.2.74 Compartmental Diffusion	297
297	18.2.83	18.2.75 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.84	18.2.76 Topical Drug Delivery (TDD)	297
297	18.2.85	18.2.77 Transdermal Drug Delivery (TDD)	297
297	18.2.86	18.2.78 Diffusion Coefficient	297
297	18.2.87	18.2.79 Compartmental Diffusion	297
297	18.2.88	18.2.80 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.89	18.2.81 Topical Drug Delivery (TDD)	297
297	18.2.90	18.2.82 Transdermal Drug Delivery (TDD)	297
297	18.2.91	18.2.83 Diffusion Coefficient	297
297	18.2.92	18.2.84 Compartmental Diffusion	297
297	18.2.93	18.2.85 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.94	18.2.86 Topical Drug Delivery (TDD)	297
297	18.2.95	18.2.87 Transdermal Drug Delivery (TDD)	297
297	18.2.96	18.2.88 Diffusion Coefficient	297
297	18.2.97	18.2.89 Compartmental Diffusion	297
297	18.2.98	18.2.90 Mechanism of <i>In Vivo</i> Penetration	297
297	18.2.99	18.2.91 Topical Drug Delivery (TDD)	297
297	18.2.100	18.2.92 Transdermal Drug Delivery (TDD)	297